{"entity":{"id":"csf3r","kind":"target","name":"G-CSF receptor (CSF3R)","aka":[],"tldr":"The receptor that tells the bone marrow to make neutrophils. Filgrastim and pegfilgrastim stimulate it to shorten the dangerous low-neutrophil period after chemotherapy, cutting the risk of febrile neutropenia.","summary":"The granulocyte colony-stimulating factor receptor on myeloid progenitors drives neutrophil production and release through JAK2 and STAT3 signalling. Recombinant G-CSF (filgrastim) and its long-acting pegylated form (pegfilgrastim) are given after myelosuppressive chemotherapy to shorten neutropenia and are recommended when the regimen carries a high risk of febrile neutropenia. They also mobilise stem cells before autologous transplantation. Activating CSF3R mutations define chronic neutrophilic leukaemia, which responds to the JAK inhibitor ruxolitinib.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Granulocyte_colony-stimulating_factor_receptor","links":[{"label":"UniProt Q99062: CSF3R","url":"https://www.uniprot.org/uniprotkb/Q99062/entry"}],"tags":[],"related":["jak2"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["filgrastim","pegfilgrastim"],"companies":[],"institutions":[],"pathways":[],"terms":["neutropenia","febrile-neutropenia"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"symbol":"CSF3R","role":[],"sources":[],"specificity":"lineage-antigen","distribution":"one-type","specificityNote":"Lineage antigen shared with normal granulocytes: HPA blood lineage lineage enriched at or above 25 nTPM, and 1 antibody (Eflapegrastim) aim at it, so normal cells of the lineage are hit too. HPA CSF3R: RNA tissue enhanced (bone marrow 184 nTPM, lung 134 nTPM, lymphoid tissue 375 nTPM); blood lineage lineage enriched (granulocytes 1,924 nTPM); high antibody staining in 1 normal tissue. Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Myeloid neoplasms); approvals of single-target medicines aimed at it also list Breast cancer (all types), not counted; Open Targets associates it with 2 specific cancer types at or above 0.5 (myelodysplastic syndrome, acute myeloid leukemia); the corpus evidence decides and the Open Targets list is quoted for comparison. (Rule 5 of scripts/fetch-target-specificity.ts.)","specificitySources":[{"label":"Human Protein Atlas CSF3R tissue","url":"https://www.proteinatlas.org/ENSG00000119535-CSF3R/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Human Protein Atlas CSF3R pathology","url":"https://www.proteinatlas.org/ENSG00000119535-CSF3R/pathology","note":"patients per staining level per cancer type (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000119535 associations","url":"https://platform.opentargets.org/target/ENSG00000119535/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:2439","ensembl":"ENSG00000119535","uniprot":"Q99062","entrez":"1441","firstDescribed":1990,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Larsen et al, J. Exp. Med, 1990, \"Expression cloning of a human granulocyte colony-stimulating factor receptor: a structural mosaic of hematopoietin receptor, immunoglobulin, and fibronectin domains\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/2147944/","biology":"Cytokine receptor on neutrophil progenitors signalling through JAK2 and STAT3; agonised by recombinant G-CSF.","whereFound":["Supportive care after chemotherapy (all cancers)","Chronic neutrophilic leukaemia (activating mutations)"],"targetClass":"other","prevalence":[{"cancerId":"myeloproliferative-neoplasms","pct":59,"measure":"Activating CSF3R mutation in chronic neutrophilic leukaemia or atypical BCR-ABL1-negative CML, 16 of 27 patients","source":"https://doi.org/10.1056/NEJMoa1214514","note":"Two mutation regions with different kinase dependencies (SRC family or JAK); ruxolitinib response reported in a JAK-type case"}]},"route":"/targets/csf3r/","neighbours":{"target":[{"id":"csf2ra","kind":"target","name":"GM-CSF receptor (CSF2RA)","route":"/targets/csf2ra/"},{"id":"jak2","kind":"target","name":"JAK2","route":"/targets/jak2/"}],"drug":[{"id":"eflapegrastim","kind":"drug","name":"Eflapegrastim","route":"/drugs/eflapegrastim/"},{"id":"filgrastim","kind":"drug","name":"Filgrastim (G-CSF)","route":"/drugs/filgrastim/"},{"id":"lenograstim","kind":"drug","name":"Lenograstim","route":"/drugs/lenograstim/"},{"id":"pegfilgrastim","kind":"drug","name":"Pegfilgrastim","route":"/drugs/pegfilgrastim/"}],"term":[{"id":"febrile-neutropenia","kind":"term","name":"Febrile neutropenia","route":"/terms/febrile-neutropenia/"},{"id":"neutropenia","kind":"term","name":"Neutropenia","route":"/terms/neutropenia/"}]}}